Edison Investment Research Limited 
Edison Investment Research Limited: Basilea Pharmaceutica (BSLN): Derazantinib spearheads oncology portfolio 
05-March-2021 / 07:00 GMT/BST 
=---------------------------------------------------------------------------------------------------------------------- 
 
London, UK, 5 March 2021 
 
Basilea Pharmaceutica (BSLN): Derazantinib spearheads oncology portfolio 
Basilea has successfully brought two anti-infective drugs to the market. Lead product Cresemba continues to benefit 
from ongoing launches by multiple partners including Astellas (US) and Pfizer (ex-US). Longer-term value creation is 
dependent on crystallising the mid-/late-stage oncology portfolio. Three ongoing Phase II trials (FIDES-01/02/03) will 
define lead R&D asset derazantinib's utility in intrahepatic cholangiocarcinoma (iCCA; bile duct cancer), urothelial 
cancer and gastric cancer. Lisavanbulin, a unique, internally developed asset, has progressed into a proof-of-concept 
Phase II biomarker-driven trial in recurrent glioblastoma (GBM) (interim results expected H221). Our forecast 
profitability in 2022 is dependent on the late-stage clinical development strategy for derazantinib and lisavanbulin. 
We value Basilea at CHF1.17bn or CHF99 per share. 
 
Our valuation is CHF1.17bn or CHF99 per share, from CHF1.14bn or CHF106 per share. We have made minor adjustments to 
the model and increased the probability of success for lisavanbulin to 35% from 20%, and derazantinib to 50% from 40%, 
reflecting pipeline progression and encouraging data readouts. Our core underlying assumptions are unchanged. Our 
valuation reflects CHF77.9m net debt at 31 December 2020, excluding the gross CHF45.75m post-period capital raise. 
 
Click here to view the full report or here to sign up to receive research as it is published. 
 
All reports published by Edison are available to download free of charge from its website 
www.edisongroup.com 
About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the 
widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, 
family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the 
darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings. 
Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. 
Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in 
Athens, Johannesburg and Sydney. 
Edison is authorised and regulated by the Financial Conduct Authority. 
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not 
solicitations to buy or sell any securities. 
For more information, please contact Edison: 
Dr Susie Jana     +44 (0)20 3077 5700    healthcare@edisongroup.com 
Dr John Priestner  +44 (0)20 3077 5700    healthcare@edisongroup.com 
Learn more at www.edisongroup.com and connect with Edison on: 
LinkedIn        https://www.linkedin.com/company/edison-group-/ 
Twitter           www.twitter.com/Edison_Inv_Res 
YouTube       www.youtube.com/edisonitv 
=---------------------------------------------------------------------------------------------------------------------- 
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=----------------------------------------------------------------------------------------------------------------------

1173155 05-March-2021

(END) Dow Jones Newswires

March 05, 2021 02:00 ET (07:00 GMT)